Skip to main content
SpringerLink
Log in

The success of NHS England’s Innovative Medicines Fund will depend on its operational details

  • Correspondence
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE & NHS England. https://www.england.nhs.uk/wp-content/uploads/2022/06/B1686-the-innovate-medicines-fund-principles-june-2022.pdf (2022).

  2. Lievens, Y. et al. Lancet Oncol. 20, e112–e123 (2019).

    Article  PubMed  Google Scholar 

  3. NICE. https://www.nice.org.uk/guidance/gid-tag387/documents/appraising-life-extending-end-of-life-treatments-paper2 (2009).

  4. NICE. https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741 (2022).

  5. Nguyen, V. T. et al. BMC Med. 19, 279 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hernán, M. A. et al. J. Clin. Epidemiol. 79, 70–75 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Naci, H. et al. Br. Med. J. 366, l5221 (2019).

    Article  Google Scholar 

  8. James, N. D. et al. BJU Int. 103, 464–469 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Aggarwal, A. et al. Ann. Oncol. 28, 1738–1750 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. NHS England. https://www.england.nhs.uk/wp-content/uploads/2021/02/B1688-nhs-commercial-framework-for-new-medicines-june-22.pdf (2022).

Download references

Acknowledgements

We thank A. Miners, R. Grieve and J. Cairns for helpful comments on earlier versions of this article.

Author information

Authors and Affiliations

  1. Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK

    Aris Angelis, Ajay Aggarwal & Andrew Briggs

  2. Department of Health Policy and LSE Health, London School of Economics and Political Science, London, UK

    Aris Angelis

  3. Department of Oncology, Guy’s & St Thomas’ NHS Trust, London, UK

    Ajay Aggarwal

Authors
  1. Aris Angelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Briggs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aris Angelis.

Ethics declarations

Competing interests

A. Angelis was a 2021–2022 National Institute for Health and Care Excellence (NICE) Scholar; has received research grants from Novartis and Krystal Biotech and consultancy fees from the Department of Health and Social Care and the European Commission; and shares ownership in a health tech company developing software tools for decision-making. A.B. has acted as consultant to various commercial companies that have products funded through the NHS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Angelis, A., Aggarwal, A. & Briggs, A. The success of NHS England’s Innovative Medicines Fund will depend on its operational details. Nat Med 29, 289–291 (2023). https://doi.org/10.1038/s41591-023-02206-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02206-w

  • Springer Nature America, Inc.

Search

Navigation